Jpmorgan Chase & CO Pyxis Oncology, Inc. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 27,076 shares of PYXS stock, worth $28,429. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,076
Previous 21,977
23.2%
Holding current value
$28,429
Previous $80,000
48.75%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding PYXS
# of Institutions
100Shares Held
24.3MCall Options Held
993KPut Options Held
42.6K-
Laurion Capital Management LP New York, NY3.63MShares$3.81 Million0.11% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.98MShares$3.13 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$2.93 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.44MShares$2.56 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.08MShares$1.14 Million0.0% of portfolio
About Pyxis Oncology, Inc.
- Ticker PYXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,096,400
- Market Cap $36.9M
- Description
- Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...